BriaCell Therapeutics Corp. priced its initial public offering at $5.59 a share, to list on the Nasdaq under the symbol BCTXL. It filed a Form S-1 registration statement for an initial public offering on April 22, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, January 14, 2026).
Who owns BriaCell Therapeutics Corp.?
Sell to companies like BriaCell Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
BriaCell Therapeutics Corp. filed a Form S-1 registration statement for an initial public offering on 2025-04-22. It has amended it 3 times. It filed its final prospectus on 2026-01-14, at a public offering price of $5.59 per share. Each fact below is quoted from the filing named with it.
Also on the record for BriaCell Therapeutics Corp.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 23, 2026 | Stake report, Schedule 13G, by Kenneth Griffin | 9.99% of the class | 5%+ stakes | Source |
| November 7, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 4.9% of the class | 5%+ stakes | Source |
| October 10, 2025 | Stake report, Schedule 13G, by Plambeck Jeremy Myung Jae | 100% of the class | 5%+ stakes | Source |
| July 28, 2025 | Stake report, Schedule 13G, by Richard Abbe | 9.1% of the class | 5%+ stakes | Source |
| July 22, 2025 | Stake report, Schedule 13G, by CVI Investments, Inc. | 5.7% of the class | 5%+ stakes | Source |
| July 21, 2025 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 4.9% of the class | 5%+ stakes | Source |
Check before you invest in BriaCell Therapeutics Corp.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on BriaCell Therapeutics Corp. and the records around it.
BriaCell Therapeutics Corp. elsewhere on the record
- 5%+ stake filings Jan 2026
- Who owns it
Companies that share a holder
- Iroquois Capital Management, LLC also filed stake reports on 13 other companies: 22nd Century Group (Aug 2026), XWELL, Inc. (Aug 2026), Clearmind Medicine Inc. (Aug 2026)
- CVI Investments, Inc. also filed stake reports on 48 other companies: Pine Tree Acquisition Corp. (Oct 2026), Sunshine Biopharma Inc. (Oct 2026), Outlook Therapeutics, Inc. (Aug 2026)
- Citadel Advisors LLC also filed stake reports on 58 other companies: Quantinuum Inc. (Oct 2026), REALLOYS INC. (Oct 2026), STARFIGHTERS SPACE, INC. (Oct 2026)
Also filing to list on the Nasdaq
IPO filings on the Nasdaq in Q1 2026, newest first.
- Texxon Holding Ltd (Mar 2026)
- VISTEK LTD (Mar 2026)
- FBS Global Ltd (Feb 2026)
- Figure Technology Solutions, Inc. (Feb 2026)
Watch BriaCell Therapeutics Corp.
Get an email when BriaCell Therapeutics Corp. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BriaCell Therapeutics Corp.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BriaCell Therapeutics Corp.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BriaCell Therapeutics Corp. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
The Warrants have been approved for listing on Nasdaq under the symbol “BCTXL”.From the 424B4 filed 2026-01-14
Shares offered
4,677,202 shares, based on an assumed public offering price of $8.95 per share (which is the last reported sale price of our common shares on Nasdaq on December 19, 2025) and assumes no sale of Pre-funded Units, which, if sold, would reduce the number of common shares that we are offering on a one-for-one basis.From the S-1 filed 2025-12-23
Offering price
After giving effect to the Offering and our sale of the Common Units in the Offering at the public offering price of $5.59 per Common Unit (and $5.589 per Pre-funded Units), and after deducting the placement agent fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of October 31, 2025, would have been $36.8 million, or $5.94 per common share.From the 424B4 filed 2026-01-14
Use of proceeds
We currently intend to use the net proceeds from this Offering to fund working capital requirements, general corporate purposes and the advancement of business objectives.From the 424B4 filed 2026-01-14
Net loss or income
On July 3, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq indicating that, based upon the Company’s market value of listed securities (“MVLS”) for the 33 consecutive business days from May 15, 2024, to July 2, 2024, the Company did not meet the minimum MVLS of $35,000,000, $2.5 million shareholders’ equity or $500,000 of net income from continuing operations requirements for The Nasdaq Capital Market set forth in Listing Rules 5550(b)(2), 5550(b)(1), or 5550(b)(3) (the “Rules”) required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(2).From the S-1 filed 2025-12-23
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-04-22 | Registration statement filed | S-1 |
| 2025-04-23 | Registration statement amended | S-1/A |
| 2025-04-28 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-04-28 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-07-08 | Registration statement filed | S-1 |
| 2025-07-09 | Registration statement amended | S-1/A |
| 2025-07-10 | Registration statement amended | S-1/A |
| 2025-07-16 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-12-23 | Registration statement filed | S-1 |
| 2026-01-14 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for BriaCell Therapeutics Corp.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.